Showing results (91-100 of 109) with videos related to
Sort By:
Pageof 11
Leukemia|August 3, 2022
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trialNikolaus Jahn, Ekaterina Jahn, Maral Saadati, et al.Journal of the National Comprehensive Cancer Network : JNCCN|October 12, 2012
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013Kenneth C Anderson, Melissa Alsina, William Bensinger, et al.Blood|March 11, 2025
Social Determinants of Health and Access to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid LeukemiaNatalie Wuliji, Salene M W Jones, Ted A Gooley, et al.Blood|December 30, 2015
Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignanciesMaya Lewinsohn, Anna L Brown, Luke M Weinel, et al.Blood|June 8, 2017
Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemiaEytan M Stein, Courtney D DiNardo, Daniel A Pollyea, et al.The New England Journal of Medicine|June 24, 2017
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 MutationRichard M Stone, Sumithra J Mandrekar, Ben L Sanford, et al.Leukemia|July 28, 2021
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study resultsFrank G Rücker, Ling Du, Tamara J Luck, et al.Leukemia|November 7, 2023
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AMLGuillermo Garcia-Manero, Nikolai A Podoltsev, Megan Othus, et al.Blood|October 19, 2022
An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AMLMohamed L Sorror, Ted A Gooley, Barry E Storer, et al.Blood|August 5, 2021
Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemiaMohamed L Sorror, Barry E Storer, Amir T Fathi, et al.Pageof 11